Prognostic importance of PSA response in patients who received Lutetium-177 PSMA treatment for castration resistant prostate cancer.

CONCLUSIONS: Serum PSA level during RLT with Lu-177 PSMA remains a clinically significant factor to predict OS times. About twenty percent of patients who were not responder after the first cycle could become responder after the last cycle. However, patients without PSA response after completion of all cycles should be closely followed-up. Non- responder patients can achieve a response with further treatments. PMID: 31602963 [PubMed - as supplied by publisher]
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research